METAL PORPHYRIN CATALYZED OLEFIN AZIRIDINATION WITH SULFONYL AZIDES

STATEMENT OF GOVERNMENT RIGHTS

[0001] This invention was made with Government support under grant number NSF #0711024, awarded by the National Science Foundation, Division of Chemistry, and under grant number CRIF: MU-0443611 , awarded by the National Science Foundation. The Government has certain rights in the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application Serial No. 61/041,206, filed March 31 , 2008, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0003] The present invention generally relates to a catalytic system for and the aziridination of olefins and, in one embodiment, the cobalt porphyrin catalyzed aziridination of aromatic olefins with arylsulfonyl azides.

BACKGROUND

[0004] Metal-catalyzed olefin aziridination is a fundamentally and practically important chemical process that has received increasing research attention. (Muller et al., Chem. Rev. 2003, 103, 2905; Hu, X.E., Tetrahedron 2004, 60, 2701.) The resulting aziridines, the smallest nitrogen-containing heterocyclic compounds, are key elements in many biologically and pharmaceutically interesting compounds and serve as a class of versatile synthons for preparation of functionalized amines. Since the introduction of PhI=NTs as a nitrene source more than three decades ago, considerable progress has been made in metal-catalyzed olefin aziridination with PhI=NTs and related iminoiodane derivatives, including the notable recent developments with the use of their in situ variants. (Yamada et al., Chem. Lett. 1975, 361. For recent examples with PhI=NTs: Klotz et al., Chem. Commun. 2007, 2063; Zdilla et al., J. Am. Chem. Soc. 2006, 128,

16971 ; Cui et al., J. Am. Chem. Soc. 2003, 125, 16202. For recent in situ variants, see: Esteoule et al., Synthesis 2007, 1251 ; Guthikonda et al., Tetrahedron 2006, 62, 11331 ; Li et al., J. Org. Chem. 2006, 71 , 5876; Xu et al., Org. Lett. 2008, 10, 1497. For other approaches, see: Antilla et al., J. Am. Chem. Soc. 1999, 121 , 5099; Williams et al., J. Am. Chem. Soc. 2004, 126, 1612; Vyas et al., Org. Lett. 2004, 6, 1907; Catino et al., Org. Lett. 2005, 7, 2787.) Despite these advances, the search for alternative nitrene sources is warranted as the use of PhI=NTs has met with several difficulties. Besides its short shelf life and poor solubility in common solvents, aziridination with PhI=NTs generates a stoichiometric amount of PhI as a by-product. In view of the similarity to diazo reagents for carbene transfer processes, azides should have the potential to serve as a general class of nitrene sources for metal-mediated nitrene transfer reactions, including aziridination. In addition to their wide availability and ease of synthesis, azide-based nitrene transfers would generate chemically stable and environmentally benign nitrogen gas as the only by-product. Despite these attributes, only a few catalytic systems have been developed that can effectively catalyze the decomposition of azides for aziridination. (Scriven et al., Chem. Rev. 1988, 88, 297; Brase et al., Angew. Chem., Int. Ed. 2005, 44, 5188; Kwart et al., J. Am. Chem. Soc. 1967, 89, 1951 ; Li et al., J. Am. Chem. Soc. 1995, 117, 5889; Cenini et al., Coord. Chem. Rev. 2006, 250, 1234; Piangiolino et al., Eur. J. Org. Chem. 2007, 743; Katsuki, T. Chem. Lett. 2005, 1304; Kawabata et al., Chem. Asian J. 2007, 2, 248. For a Co- catalyzed hydroazidation of olefins, see: Waser et al., J. Am. Chem. Soc. 2005, 127, 8294. For a Brønsted acid-promoted process, see: Mahoney et al., J. Am. Chem. Soc. 2005, 127, 1354.)

SUMMARY OF THE INVENTION

[0005] Among the various aspects of the present invention, therefore, is a process for the aziridination of olefins, and a cobalt catalyst for olefin aziridination.

[0006] Briefly, therefore, one aspect of the present invention is a process for the aziridination of an olefin, the process comprising treating the olefin with a sulfonyl azide in the presence of a metal porphyrin complex.

[0007] Another aspect of the present invention is a process for the aziridination of an olefin, the process comprising treating the olefin with a sulfonyl azide in the presence of a metal porphyrin complex, wherein the olefin corresponds to Formula 1 , the sulfonyl azide corresponds to Formula A:

Formula 1

O

Rio S N ₃

O

Formula A and Ri, R ₂ , R ₃ , R4 and R1 ₀ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo or EWG (electron-withdrawing group).

[0008] Another aspect of the present invention is a process for the aziridination of an olefin, the process comprising treating the olefin with a sulfonyl azide in the presence of a metal porphyrin complex, wherein the olefin corresponds to Formula 5, the sulfonyl azide corresponds to Formula B:

Formula B and R ₄ and Ar are independently aryl.

[0009] Another aspect of the present invention is a cobalt porphyrin catalyst corresponding to the formula:

[0010] Other aspects of the invention will be, in part, apparent, and, in part, pointed out hereinafter.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] In accordance with certain aspects of the present invention, a process and catalysts are provided for olefin aziridination with azides. In one aspect, a cobalt porphyrin complex is used as the catalyst. In another aspect, any of a wide range of olefins are aziridinated using any of a wide range of azides. In a preferred embodiment, an aromatic olefin is aziridinated with an arylsulfonylazide.

[0012] Olefins

[0013] In general, the olefin, also referred to herein as an alkene, may be any of a wide range of olefins. In one embodiment, the alkene is a terminal alkene. For example, the alkene may be a monosubstituted terminal alkene or a disubstituted terminal alkene. In another embodiment, the alkene is an internal alkene. For example, the alkene may be a disubstituted, trisubstituted or tetrasubstituted internal alkene. If disubstituted, the internal alkene may have the cis or trans configuration. In one embodiment, the olefin is an aromatic, monosubstituted terminal alkene.

[0014] In one embodiment, the olefin corresponds to Formula 1 :

Formula 1 wherein Ri and R ₂ are substituents of the α-carbon of the ethylenic bond (also referred to as an olefinic bond), and R ₃ and R ₄ are substituents of the β-carbon of the ethylenic bond. R ₁ , R ₂ , R3, and R ₄ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo or EWG (electron-withdrawing group). In one embodiment, Ri is hydrogen. In another embodiment, Ri is alkyl, substituted alkyl, or aryl. In one embodiment, R ₂ is hydrogen. In another embodiment, R ₂ is alkyl, substituted alkyl, or aryl. In one embodiment, R ₃ is hydrogen. In another embodiment, R ₃ is alkyl, substituted alkyl, or aryl. In one embodiment, R ₄ is hydrogen. In another embodiment, R ₄ is alkyl, substituted alkyl, or aryl. In one embodiment, two of Ri, R ₂ , R ₃ and R ₄ are hydrogen. In another embodiment, three of Ri, R ₂ , R ₃ , and R ₄ are hydrogen. In one embodiment, Ri, R ₂ and the α-carbon, or R ₃ , R ₄ and the β-carbon, form a carbocyclic or heterocyclic ring. In another embodiment, Ri, R ₃ , the α-carbon, and the β-carbon, or R ₂ , R ₄ , the α-carbon, and the β-carbon form a carbocyclic or heterocyclic ring. In another embodiment, Ri, R ₄ , the α-carbon, and the β-carbon, or R ₂ , R ₃ , the α-carbon, and the β-carbon form a carbocyclic or heterocyclic ring. In one preferred embodiment, at least one of Ri, R ₂ , R ₃ , and R ₄ is alkyl, aryl, substituted phenyl, -CN, -C(O)R ₂₂ , or -C(O)OR ₂₂ wherein R ₂₂ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl. In another presently preferred embodiment, one of Ri, R ₂ , R ₃ , and R ₄ is aryl and the others are hydrogen; for example, in this embodiment, Ri, R ₂ , and R ₃ may be hydrogen and R ₄ is aryl, optionally substituted with any of the substituents identified elsewhere herein in connection with the substituted hydrocarbyl substituents.

[0015] When the olefin corresponds to Formula 1 and one of Ri, R ₂ , R ₃ , and R ₄ is hydrogen, e.g., R ₂ is hydrogen, the olefin corresponds to Formula 2:

wherein Ri is a substituent of the α-carbon of the ethylenic bond, R ₃ and R ₄ are substituents of the β-carbon of the ethylenic bond, and Ri, R ₃ , and R ₄ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, Ri is hydrogen and the olefin is a mono or disubstituted terminal alkene. In another embodiment, Ri is alkyl, substituted alkyl or aryl and the olefin is a disubstituted or a trisubstituted internal alkene. In one embodiment, R ₃ is hydrogen. In another embodiment, R ₃ is alkyl, substituted alkyl or aryl. In one embodiment, R ₄ is hydrogen. In another embodiment, R ₄ is alkyl, substituted alkyl or aryl. In one embodiment, two of Ri, R ₃ and R ₄ are hydrogen. In one embodiment, R ₃ , R ₄ and the β-carbon form a carbocyclic or heterocyclic ring. In another embodiment, Ri, R ₃ , the α-carbon, and the β-carbon form a carbocyclic or heterocyclic ring. In another embodiment, Ri, R ₄ , the α-carbon, and the β-carbon form a carbocyclic or heterocyclic ring. In one preferred embodiment, at least one of Ri, R ₃ , and R ₄ is alkyl, phenyl, substituted phenyl, -CN, -C(O)R22, or -C(O)OR ₂ 2 wherein R22 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl.

[0016] When the olefin corresponds to Formula 1 , R ₂ is hydrogen, and one of R ₃ and R ₄ is hydrogen, the olefin corresponds to Formula 3-cis or Formula 3-trans:

wherein Ri is a substituent of the α-carbon of the ethylenic bond, and R ₃ and R ₄ are substituents of the β-carbon of the ethylenic bond. R ₁ , R ₃ and R ₄ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, R ₁ is hydrogen. In another embodiment, R ₁ is alkyl, substituted alkyl or aryl. In one

embodiment, R ₃ is hydrogen. In another embodiment, R ₃ is alkyl, substituted alkyl or aryl. In one embodiment, R ₄ is hydrogen. In another embodiment, R ₄ is alkyl, substituted alkyl or aryl. In one embodiment, R ₁ , R ₃ , the α-carbon, and the β-carbon form a carbocyclic or heterocyclic ring. In another embodiment, R ₁ , R ₄ , the α-carbon, and the β-carbon form a carbocyclic or heterocyclic ring. In one preferred embodiment, at least one of R ₁ , R ₃ , and R ₄ is alkyl, alkenyl, heterocyclo, phenyl, substituted phenyl, -CN, -C(O)R ₂ 2, or -C(O)OR22 wherein R22 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl.

[001 T\ When the olefin corresponds to Formula 1 and two of the substituents on the same ethylenic carbon, e.g., Ri and R ₂ , are each hydrogen, the olefin is a terminal alkene, corresponding to Formula 4:

wherein R ₃ and R ₄ are substituents of the β-carbon of the ethylenic bond, and are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, R ₃ is hydrogen. In another embodiment, R ₃ is alkyl, substituted alkyl or aryl. In one embodiment, R ₄ is hydrogen. In another embodiment, R ₄ is alkyl, substituted alkyl or aryl. In one embodiment, R ₃ , R ₄ , and the β-carbon form a carbocyclic or heterocyclic ring. In one preferred embodiment, at least one of R ₃ and R ₄ is alkyl, alkenyl, heterocyclo, phenyl, substituted phenyl, -CN, -C(O)R ₂ 2, or -C(O)OR ₂₂ wherein R ₂₂ is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl.

[0018] When the olefin corresponds to. Formula 1 and three of Ri, R ₂ , R ₃ , and R ₄ are hydrogen, e.g., R ₁ , R ₂ , and R ₃ are hydrogen, the olefin is a terminal olefin corresponding to Formula 5:

wherein R ₄ is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, R ₄ is alkyl, substituted alkyl or aryl. In another embodiment, R ₄ is aryl. For example, R ₄ may be phenyl, substituted phenyl, naphthyl, or substituted naphthyl. By way of further example, in one embodiment, R ₄ is preferably phenyl or naphthyl, optionally substituted with alkyl, heterosubstituted alkyl, or a hetero atom containing substituent selected from the group consisting of halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxyl, protected hydroxy, keto, acyl, acyloxy, nitro, amino, amido, nitro, cyano, thiol, ketals, acetals, esters and ethers. In a further preferred embodiment, R ₄ is phenyl, tolyl (CH ₃ C ₆ H ₄ -), tert-butyl phenyl, chlorophenyl, bromophenyl, fluorophenyl, trifluoromethyl phenyl, or naphthyl.

[0019] In a preferred embodiment, the olefin is an aromatic olefin corresponding to the following Formula 6:

Formula 6 wherein R ₅ is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, halo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, keto, acyl, acyloxy, nitro, amino, amido, cyano, or thiol. In one embodiment, R ₅ is hydrogen. In another embodiment, R ₅ is alkyl. In another embodiment, R ₅ is alkyl substituted with a substituent selected from the group consisting of halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, keto, acyl, acyloxy, nitro, amino, amido, nitro, cyano, thiol, ketals, acetals, esters and ethers. In one such embodiment, R ₅ is a halogen. In one preferred embodiment, R ₅ is methyl, butyl, chloro, bromo, fluoro, trifluoromethyl, alkoxy, hydroxy, keto, acyl, acyloxy, amino, amido, nitro, cyano, or thiol. In one preferred embodiment, R ₅ is methyl, butyl, chloro, bromo, fluoro, trifluoromethyl, alkoxy, hydroxy, amino, amido, nitro, or cyano. In one

preferred embodiment, R ₅ is methyl, tert-butyl, chlorine, bromine, fluorine, or trifluoromethyl.

[00201 Azides

[0021] In general, the olefin is aziridinated with a nitrene source. Preferably, the nitrene precursor is an azide reagent (also sometimes referred to herein as an azide compound) wherein the nitrene is generated by the removal of N ₂ as nitrogen gas from the solution.

[0022] In one embodiment, the nitrene source is a sulfonyl azide corresponding to the following Formula A: O

R ₁₀ S N ₃

O Formula A wherein Ri ₀ is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, Ri ₀ is alkyl, alkenyl, alkynyl, aryl, alkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, or substituted aryl.

[0023] In one presently preferred embodiment, Rio is aryl. For example, in this embodiment Rio may be phenyl or substituted phenyl. By way of further example, the phenyl may be alkyl substituted (e.g., tolyl) or heterosubstituted. If heterosubstituted, the phenyl moiety is preferably substituted with a halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, acyl, acyloxy, nitro, amino, amido, cyano, or thiol moiety. For example, in one embodiment Rio is phenyl, naphthyl, tolyl, methoxyphenyl, ethanoylamine phenyl (CH ₃ C(O)NHC ₆ H ₄ -) or other amido substituted phenyl, cyanophenyl, or nitrophenyl.

[0024] In a preferred embodiment, the nitrene source is an arylsulfonyl azide corresponding to the following Formula B:

Formula B wherein Ar is aryl, including optionally substituted aryl. In a preferred embodiment, Ar is phenyl, tolyl, methoxy phenyl, ethanoylamine phenyl (CH ₃ C(O)NHC ₆ H ₄ -) or other amido substituted phenyl, cyanophenyl, nitrophenyl, or naphthyl.

[0025] Metal Porphyrin Complex

[0026] An aspect of the present invention is a process for the aziridination of olefins in the presence of a catalyst. In an embodiment, the catalyst is a metal porphyrin complex. In one embodiment, the metal of the metal porphyrin complex is a transition metal. Thus, for example, the metal, M, may be any of the 30 metals in the 3d, 4d, and 5d transition metal series of the Periodic Table of the Elements, including the 3d series that includes Sc, Ti, V ₁ Cr, Mn, Fe, Co, Ni, Cu, and Zn; the 4d series that includes Y, Zr, Nb, Mo, Tc, Ru ₁ Rh, Pd, Ag and Cd; and the 5d series that includes Lu, Hf, Ta, W, Re ₁ Os ₁ Ir, Pt, Au and Hg. In some embodiments, M is a transition metal from the 3d series. In some embodiments, M is selected from the group consisting of Co, Zn, Fe, Ru, Mn, and Ni. In some embodiments, M is selected from the group consisting of Co, Fe, and Ru. In some embodiments, M is Co.

[0027] The porphyrin with which the metal is complexed may be any of a wide range of porphyrins known in the art. Exemplary porphyrins are described in U.S. Patent Publication Nos. 2005/0124596 and 2006/0030718 and U.S. Patent No. 6,951 ,935 (each of which is incorporated herein by reference, in its entirety). Exemplary porphyrins are also described in Chen et al., Bromoporphyrins as Versatile Synthons for Modular Construction of Chiral Porphyrins: Cobalt-Catalyzed Highly Enantioselective and Diastereoselective Cyclopropanation (J. Am. Chem. Soc. 2004), which is incorporated herein by reference in its entirety.

[0028] In a preferred embodiment, the porphyrin is complexed with cobalt. The porphyrin with which cobalt is complexed may be any of a wide range of porphyrins

known in the art. Exemplary porphyrins are described in U.S. Patent Publication Nos. 2005/0124596 and 2006/0030718 and U.S. Patent No. 6,951 ,935 (each of which is incorporated herein by reference, in its entirety). Exemplary porphyrins are also described in Chen et al., Bromoporphyrins as Versatile Synthons for Modular Construction of Chiral Porphyrins: Cobalt-Catalyzed Highly Enantioselective and Diastereoselective Cyclopropanation (J. Am. Chem. Soc. 2004), which is incorporated herein by reference in its entirety.

[0029] Generally, a preferred cobalt for aziridinating olefins is a cobalt porphyrin complex. In one embodiment, the cobalt porphyrin complex is a cobalt (II) porphyrin complex. In one particularly preferred embodiment, the cobalt porphyrin complex is a D ₂ -symmetric chiral porphyrin complex corresponding to the following structure:

wherein each Zi, Z ₂ , Z ₃ , Z ₄ , Z ₅ and Z ₆ are each independently selected from the group consisting of X, H ₁ alkyl, substituted alkyls, arylalkyls, aryls and substituted aryls; and X is selected from the group consisting of halogen, triflouromethanesulfonate (OTf), haloaryl and haloalkyl. In a preferred embodiment, Z ₂ , Z ₃ , Z ₄ and Z ₅ are hydrogen, Z ₁ is a substituted phenyl, and Z ₆ is substituted phenyl, and Zi and Z ₆ are different. In one particularly preferred embodiment, Z ₂ , Z ₃ , Z ₄ and Z ₅ are hydrogen, Z ₁ is substituted phenyl, and Z ₆ is substituted phenyl and Zi and Z ₆ are different and the porphyrin is a chiral porphyrin. In one even further preferred embodiment, Z ₂ , Z ₃ , Z ₄ and Z ₅ are hydrogen, Zi is substituted phenyl, and Z ₆ is substituted phenyl and Z^ and Z ₆ are

different and the porphyrin has D ₂ -symmetry. In one embodiment, Z ₂ , Z ₃ , Z ₄ and Z ₅ are hydrogen, Z ₁ is 3,5-di(tert-butyl)phenyl, and Zβ is 2,6-di(isobutylamine)phenyl.

[0030] Exemplary cobalt (II) porphyrins include the following:

f003nAziridination Reactions

[0032] accordance with one embodiment of the present invention, an alkene is converted to an aziridine as illustrated in Reaction Scheme A:

Reaction Scheme A

wherein [M(Por*)] is a metal porphyrin complex, Ri, R2, R ₃ and R ₄ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo or EWG (electron- withdrawing group), and R ₁₀ is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, the metal porphyrin complex is a cobalt porphyrin complex. In one embodiment, R ₁₀ is alkyl, alkenyl, alkynyl, phenyl, alkyl, substituted alkyl, or heterosubstituted phenyl. In another embodiment, R1 ₀ is phenyl, tolyl, methoxyphenyl, ethanoylamine phenyl, cyanophenyl, nitrophenyl, or naphthyl. In one embodiment, Ri is hydrogen. In another embodiment, Ri is alkyl, substituted alkyl or aryl. In one embodiment, R ₂ is hydrogen. In another embodiment, R ₂ is alkyl, substituted alkyl or aryl. In one embodiment, R ₃ is hydrogen. In another embodiment, R ₃ is alkyl, substituted alkyl or aryl. In one embodiment, R ₄ is hydrogen. In another

embodiment, R ₄ is alkyl, substituted alkyl or aryl. In one embodiment, at least one of Ri, R ₂ , R ₃ and R ₄ is hydrogen and the other three are alkyl, substituted alkyl or aryl. In one embodiment, at least two of Ri, R ₂ , R3 and R ₄ are hydrogen and the other two are alkyl, substituted alkyl or aryl. In another embodiment, at least three of Ri, R2, R3 and R ₄ are hydrogen and the other one is alkyl, substituted alkyl or aryl. In one embodiment, Ri, R ₂ and the aziridine ring carbon to which they are bonded, or R ₃ , R ₄ and the aziridine ring carbon to which they are bonded, form a carbocyclic or heterocyclic ring. In another embodiment, Ri, R ₃ , and the aziridine ring carbons to which Ri and R ₃ are bonded, or R ₂ , R ₄ , and the aziridine ring carbons to which R ₂ and R ₄ are bonded, form a carbocyclic or heterocyclic ring. In another embodiment, Ri, R ₄ , and the aziridine ring carbons to which Ri and R ₄ are bonded, or R ₂ , R ₃ , and the aziridine ring carbons to which R ₂ and R ₃ are bonded, form a carbocyclic or heterocyclic ring.

[0033] In one embodiment, the aziridination reaction proceeds as illustrated in Reaction Scheme B:

Reaction Scheme B wherein Ri, R ₂ , and R ₃ are as previously described in connection with the olefin, R is a sulfonyl, and [L _n M] is a metal catalyst.

[0034] In one embodiment, an alkene is aziridinated as illustrated in Reaction Scheme B-1 , B-2, B-3, or B-4.

Reaction Scheme B-1

Reaction Scheme B-2

Reaction Scheme B-3

Reaction Scheme B-4

wherein [Co(Por*)] is a cobalt porphyrin complex, Ri, R ₂ , R ₃ and R ₄ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo, and R1 ₀ is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, Ri ₀ is alkyl, alkenyl, alkynyl, phenyl, alkyl, substituted alkyl, or heterosubstituted phenyl. In another embodiment, Ri ₀ is phenyl, tolyl, methoxyphenyl, ethanoylamine phenyl, cyanophenyl, nitrophenyl, or naphthyl. In one embodiment, Ri is hydrogen. In another embodiment, R ₁ is alkyl, substituted alkyl or aryl. In one embodiment, R ₂ is hydrogen. In another embodiment, R ₂ is alkyl, substituted alkyl or aryl. In one embodiment, R ₃ is hydrogen. In another embodiment, R ₃ is alkyl, substituted alkyl or aryl. In one embodiment, R ₄ is hydrogen. In another embodiment, R ₄ is alkyl, substituted alkyl or aryl. In one embodiment, at least one of R ₁ , R ₂ , R ₃ and R ₄ is hydrogen and the other two are independently alkyl, substituted alkyl or aryl. In one embodiment, at least two of R ₁ , R ₂ ,

R ₃ and R ₄ are hydrogen and the other one is alkyl, substituted alkyl or aryl. In one embodiment, Ri, R ₂ and the aziridine ring carbon to which they are bonded, or R ₃ , R ₄ and the aziridine ring carbon to which they are bonded, form a carbocyclic or heterocyclic ring. In another embodiment, Ri, R ₃ , and the aziridine ring carbons to which Ri and R ₃ are bonded, or R ₂ , R ₄ , and the aziridine ring carbons to which R ₂ and R ₄ are bonded, form a carbocyclic or heterocyclic ring. In another embodiment, Ri, R ₄ , and the aziridine ring carbons to which Ri and R ₄ are bonded, or R ₂ , R ₃ , and the aziridine ring carbons to which R ₂ and R ₃ are bonded, form a carbocyclic or heterocyclic ring.

[0035] In one preferred embodiment, an alkene is aziridinated as illustrated in Reaction Scheme C-1 :

Reaction Scheme C-1

wherein [Co(Por*)] is a cobalt porphyrin complex, Ri and R ₂ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo, and Ri ₀ is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, Ri ₀ is alkyl, alkenyl, alkynyl, phenyl, alkyl, substituted alkyl, or heterosubstituted phenyl. In another embodiment, Ri ₀ is phenyl, tolyl, methoxyphenyl, ethanoylamine phenyl (or other amido substituted phenyl), cyanophenyl, nitrophenyl, or naphthyl. In one embodiment, Ri is hydrogen. In another embodiment, Ri is alkyl, substituted alkyl or aryl. In one embodiment, R ₂ is hydrogen. In another embodiment, R ₂ is alkyl, substituted alkyl or aryl. In one embodiment, one of Ri and R ₂ is hydrogen and the other one is alkyl, substituted alkyl or aryl. In one embodiment, Ri, R ₂ and the aziridine ring carbons to which they are bonded form a carbocyclic or heterocyclic ring.

[0036] In another preferred embodiment, an alkene is converted to an aziridine as illustrated in Reaction Scheme C-2-trans:

Reaction Scheme C-2-trans

wherein [Co(Por*)] is a cobalt porphyrin complex, R ₂ and R ₃ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo, and Ri ₀ is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, R ₁₀ is alkyl, alkenyl, alkynyl, phenyl, alkyl, substituted alkyl, or heterosubstituted phenyl. In another embodiment, Ri ₀ is phenyl, tolyl, methoxyphenyl, ethanoylamine phenyl, cyanophenyl, nitrophenyl, or naphthyl. In one embodiment, R ₂ is hydrogen. In another embodiment, R ₂ is alkyl, substituted alkyl or aryl. In one embodiment, R ₃ is hydrogen. In another embodiment, R3 is alkyl, substituted alkyl or aryl. In one embodiment, one of R ₂ and R ₃ is hydrogen and the other one is alkyl, substituted alkyl or aryl. In one embodiment, R ₂ , R ₃ , and the aziridine ring carbons to which they are bonded form a carbocyclic or heterocyclic ring.

[0037] In another preferred embodiment, an alkene is converted to an aziridine as illustrated in Reaction Scheme C-2-cis:

N ₂

Reaction Scheme C-2-cis

wherein [Co(Por ^* )] is a cobalt porphyrin complex, Ri and R ₃ are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo, and R ₁₀ is hydrogen,

hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, R ₁₀ is alkyl, alkenyl, alkynyl, phenyl, alkyl, substituted alkyl, or heterosubstituted phenyl. In another embodiment, Ri ₀ is phenyl, tolyl, methoxyphenyl, ethanoylamine phenyl, cyanophenyl, nitrophenyl, or naphthyl. In one embodiment, Ri is hydrogen. In another embodiment, Ri is alkyl, substituted alkyl or aryl. In one embodiment, R ₃ is hydrogen. In another embodiment, R3 is alkyl, substituted alkyl or aryl. In one embodiment, one of Ri and R3 is hydrogen and the other one is alkyl, substituted alkyl or aryl. In one embodiment, R ₁ , R ₃ , and the aziridine ring carbons to which Ri and R ₃ are bonded form a carbocyclic or heterocyclic ring.

[0038] In another preferred embodiment, an alkene is converted to an aziridine as illustrated in Reaction Scheme D:

Reaction Scheme D

wherein [Co(Por*)] is a cobalt porphyrin complex, Ri is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo, and R ₁₀ is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo. In one embodiment, Ri ₀ is alkyl, alkenyl, alkynyl, phenyl, alkyl, substituted alkyl, or heterosubstituted phenyl. In one presently preferred embodiment, R ₁₀ is aryl. In another embodiment, Ri ₀ is phenyl, tolyl, methoxyphenyl, ethanoylamine phenyl, cyanophenyl, nitrophenyl, or naphthyl. In one embodiment, Ri is alkyl substituted alkyl, or aryl. In one presently preferred embodiment, Ri is aryl and R10 is aryl.

[0039] In a preferred embodiment, an olefin is aziridinated in the presence of an azide and a cobalt porphyrin catalyst as illustrated in Reaction Scheme 1 :

Reaction Scheme 1 wherein Ar and Ar' are independently aryl, that is, Ar and Ar' are each aryl and are the same or are different, and wherein [Co(Por)] is a cobalt porphyrin complex catalyst.

[0040] In another preferred embodiment, an olefin is converted to an aziridine in the presence of an azide and a cobalt porphyrin catalyst as illustrated Reaction Scheme 2:

Reaction Scheme 2 wherein Ar is aryl, and [Co(Por)] is a cobalt porphyrin complex catalyst. In one presently preferred embodiment, Ar is phenyl, tolyl, methoxyphenyl, ethanoylamine phenyl, cyanophenyl, nitrophenyl, or naphthyl.

[0041] In a further preferred embodiment, the cobalt catalyst aziridinates an olefin in the presence of an arylsulfonyl azide as illustrated in the following Reaction Scheme 3:

Reaction Scheme 3

wherein R ₅ is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, halo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, acyl, acyloxy, nitro, amino, amido, cyano, or thiol. In one embodiment, R ₅ is hydrogen. In another embodiment, R ₅ is alkyl. In another embodiment, R ₅ is alkyl substituted with a substituent selected from the group consisting of halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, keto, acyl, acyloxy, nitro, amino, amido, nitro, cyano, thiol, ketals, acetals, esters and ethers. In one embodiment, R ₅ is a halogen. In one preferred embodiment, R ₅ is methyl, butyl, chloro, bromo, fluoro, trifluoromethyl, alkoxy, hydroxy, keto, acyl, acyloxy, amino, amido, nitro, cyano, or thiol. In one presently preferred embodiment, R ₅ is methyl, butyl, chloro, bromo, fluoro, trifluoromethyl, alkoxy, hydroxy, amino, amido, nitro, or cyano. In another presently preferred embodiment, R ₅ is methyl, tert-butyl, chlorine, bromine, fluorine, or trifluoromethyl. In a further presently preferred embodiment, R ₅ is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, or halo, and Ar is aryl, including without limitation optionally substituted aryl. In one embodiment, R ₅ is hydrogen. In another embodiment, R ₅ is alkyl. In a further presently preferred embodiment, R ₅ is alkyl, substituted alkyl, halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxyl, protected hydroxy, acyl, acyloxy, nitro, amino, amido, cyano, or thiol, and Ar is phenyl or phenyl substituted with halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxyl, protected hydroxy, acyl, acyloxy, nitro, amino, amido, cyano, or thiol. In a further embodiment, R ₅ is methyl, tert-butyl, chlorine, bromine, fluorine, or

trifluoromethyl and Ar is phenyl, tolyl, alkoxyphenyl, amidophenyl, cyanophenyl, nitrophenyl, or naphthyl.

[0042] ABBREVIATIONS AND DEFINITIONS

[0043]The following definitions and methods are provided to better define the present invention and to guide those of ordinary skill in the art in the practice of the present invention. Unless otherwise noted, terms are to be understood according to conventional usage by those of ordinary skill in the relevant art.

[0044] The term "acyl," as used herein alone or as part of another group, denotes the moiety formed by removal of the hydroxyl group from the group -COOH of an organic carboxylic acid, e.g., RC(O)-, wherein R is R ¹ , R ¹ O-, R ¹ R ² N-, or R ¹ S-, R ¹ is hydrocarbyl, heterosubstituted hydrocarbyl, or heterocyclo and R ² is hydrogen, hydrocarbyl or substituted hydrocarbyl.

[0045] The term "acyloxy," as used herein alone or as part of another group, denotes an acyl group as described above bonded through an oxygen linkage (-O-), e.g., RC(O)O- wherein R is as defined in connection with the term "acyl."

[0046] Unless otherwise indicated, the alkenyl groups described herein are preferably lower alkenyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, and the like.

[0047] Unless otherwise indicated, the alkyl groups described herein are preferably lower alkyl containing from one to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include methyl, ethyl, propyl, isopropyl, butyl, hexyl, and the like. The substituted alkyl groups described herein may have, as substituents, any of the substituents identified as substituted hydrocarbyl substituents.

[0048] The term alkoxy or alkoxyl shall mean any univalent radical, RO ^" where R is an alkyl group.

[0049] Unless otherwise indicated, the alkynyl groups described herein are preferably lower alkynyl containing from two to eight carbon atoms in the principal chain

and up to 20 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, hexynyl, and the like.

[0050] The term "amido" as used herein alone or as part of another group, denotes the moiety formed by removal of a hydrogen from the nitrogen atom of an amide, e.g., R ¹ OC(O)N(R ² )- wherein R ¹ and R ² are independently hydrogen, hydrocarbyl, heterosubstituted hydrocarbyl, or heterocyclo. Thus, for example, amidophenyl or amido substituted phenyl may be R ¹ OC(O)N(R ² )C ₆ H ₄ - wherein R ¹ and R ² are independently hydrogen, hydrocarbyl, heterosubstituted hydrocarbyl, or heterocyclo.

[0051] The terms "aryl" or "ar" as used herein alone or as part of another group denote optionally substituted homocyclic aromatic groups, preferably monocyclic or bicyclic groups containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl. Phenyl and substituted phenyl are the more preferred aryl. The substituted aryl groups described herein may have, as substituents, any of the substituents identified as substituted hydrocarbyl substituents.

[0052] The term "azide" as used herein describes a compound with three linked nitrogen atoms, including without limitation the anion with the formula N ₃ and the functional group R _x -Ns, wherein R _x is any atom in the Periodic Table of the Elements.

[0053] The terms "EWG" and "electron withdrawing group" describes any substituent that draws electrons away from the ethylenic bond. Exemplary electron withdrawing groups include hydroxy, alkoxy, mercapto, halogens, carbonyls, sulfonyls, nitrile, quaternary amines, nitro, trihalomethyl, imine, amidine, oxime, thioketone, thioester, or thioamide. In one embodiment, the electron withdrawing group(s) is/are hydroxy, alkoxy, mercapto, halogen, carbonyl, sulfonyl, nitrile, quaternary amine, nitro, or trihalomethyl. In another embodiment, the electron withdrawing group(s) is/are halogen, carbonyl, nitrile, quaternary amine, nitro, or trihalomethyl. In another embodiment, the electron withdrawing group(s) is/are halogen, carbonyl, nitrile, nitro, or trihalomethyl. When the electron withdrawing group is alkoxy, it generally corresponds to the formula -OR where R is hydrocarbyl, substituted hydrocarbyl, or heterocyclo. When the electron withdrawing group is mercapto, it generally corresponds to the formula -SR where R is hydrogen, hydrocarbyl, substituted hydrocarbyl or heterocyclo. When the

electron withdrawing group is a halogen atom, the electron withdrawing group may be fluoro, chloro, bromo, or iodo; typically, it will be fluoro or chloro. When the electron withdrawing group is a carbonyl, it may be an aldehyde (-C(O)H), ketone (-C(O)R), ester (-C(O)OR), acid (-C(O)OH), acid halide (-C(O)X), amide (-C(O)NR _a R _b ), or anhydride (-C(O)OC(O)R) where R is hydrocarbyl, substituted hydrocarbyl or heterocyclo, Ra and Rb are independently hydrogen, hydrocarbyl, substituted hydrocarbyl or heterocyclo, and X is a halogen atom. When the electron withdrawing group is a sulfonyl, it may be an acid (-SO ₃ H) or a derivative thereof (-SO ₂ R) where R is hydrocarbyl, substituted hydrocarbyl or heterocyclo. When the electron withdrawing group is a quaternary amine, it generally corresponds to the formula -N ⁺ R _a RbR _c where R ₃ , Rb and R _c are independently hydrogen, hydrocarbyl, substituted hydrocarbyl or heterocyclo. When the electron withdrawing group is a trihalomethyl, it is preferably trifluoromethyl or trichloromethyl. In each of the foregoing exemplary electron withdrawing groups containing the variable "X", in one embodiment, X may be chloro or fluoro, preferably fluoro. In each of the foregoing exemplary electron withdrawing groups containing the variable "R", R may be alkyl. In each of the foregoing exemplary electron withdrawing groups containing the variable "R _a " and "R _b ", R _a and R _b may independently be hydrogen or alkyl.

[0054] The terms "halogen" or "halo" as used herein alone or as part of another group refer to chlorine, bromine, fluorine, and iodine.

[0055] The term "heteroatom" shall mean atoms other than carbon and hydrogen.

[0056] The term "heteroaromatic" as used herein alone or as part of another group denote optionally substituted aromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring. The heteroaromatic group preferably has 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in the ring, and may be bonded to the remainder of the molecule through a carbon or heteroatom. Exemplary heteroaromatics include furyl, thienyl, pyridyl, oxazolyl, pyrrolyl, indolyl, quinolinyl, or isoquinolinyl and the like. Exemplary substituents include one or more of the following groups: hydrocarbyl, substituted hydrocarbyl, keto, hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy, aryloxy, halogen, amido, amino, nitro, cyano, thiol, ketals, acetals, esters and ethers.

[0057] The terms "hydrocarbon" and "hydrocarbyl" as used herein describe organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl, and alkynaryl. Unless otherwise indicated, these moieties preferably comprise 1 to 20 carbon atoms. The "substituted hydrocarbyl" moieties described herein are hydrocarbyl moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or a halogen atom. These substituents include halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxyl, protected hydroxy, keto, acyl, acyloxy, nitro, amino, amido, nitro, cyano, thiol, ketals, acetals, esters and ethers.

[0058] The term porphyrin refers to a compound comprising a fundamental skeleton of four pyrrole nuclei united through the α-positions by four methane groups to form the following macrocyclic structure:

5

EXAMPLES

[0059] We recently reported a Co-based system for catalytic aziridination with azide. (Gao et al., J. Org. Chem. 2006, 71 , 6655.) It was shown that [Co(TPP)] can catalyze olefin aziridination with commercially available dipenylphosphoryl azide (DPPA) as a

convenient new nitrene source, leading to the formation of λ/-phosphorylated aziridines. In an attempt to expand the catalytic process for other azides, it was found that [Co(TPP)] was ineffective for olefination aziridination with sulfonyl azides. For example, the desired aziridines 2a-c were obtained only in 11-24% yields from styrene when the common azides 1a-c were used (See Reaction Scheme 4). Changing the catalyst to Co(TDCIPP), which was shown to be effective for aziridination with bromamine-T, produced the desired product in less than 5% yield for each of the cases (Reaction Scheme 4); except unreacted azides and styrene, no other products were observed. (Gao et al., Org. Lett. 2005, 7, 3191.) As part of our efforts to develop new porphyrin ligands to enhance Co-based catalytic processes, herein we describe the design and synthesis of a new porphyrin P1 based on potential hydrogen bonding interaction in the assumed metal-nitrene intermediate. The Co(II) complex of P1 [Co(PI)] was shown to be a highly active catalyst for aziridination of different aromatic olefins with various arylsulfonyl azides, forming the corresponding aziridines in excellent yields under mild conditions (Reaction Scheme 4). Careful control experiments showed that arylsulfonyl azides reported in this work were stable under the conditions used. But it should be noted that some of the azide compounds may be explosive and should be handled with great care.

Reaction Scheme 4. Co-Catalyzed Aziridination of Styrene with Azides.

5.0 equivalent

ArSO ₂ N ₃ (I) [Co(TPP)] [Co(TDCIPP)] [Co(PI)]

4-Me-C ₆ H ₄ SO ₂ N ₃ (Ia) 2a: 18% 2a: <5% 2a: 94%

4-MeO-C ₆ H ₄ SO ₂ N ₃ (Ib) 2b: 24% 2b: <5% 2b: 88%

4-MeC(O)NH-C ₆ H ₄ SO ₂ N ₃

2c: 11% 2c: <5% 2c: 98% (1c)

[0060] Similar to that proposed for other metal-based systems, the Co-catalyzed aziridination can be assumed to proceed via a mechanism involving a key electrophilic Co-nitrene intermediate. (Ruppel et al., Org. Lett. 2007, 9, 4889.) Accordingly, elements that can stabilize the formation of and enhance the electrophilicity of the nitrene intermediate should facilitate the catalytic cycle. Due to the existence of SO ₂ group in sulfonyl azides, the D ₂ ή-symmetric porphyrin P1 containing amide functionalities at the ortho positions of meso-phenyl groups was designed to invoke a significant hydrogen bonding interaction between the S=O and N-H unit in the supposed nitrene intermediate of [Co(PI)]. (Simple computer modeling by molecular mechanics with Spartan 04 resulted in a minimized geometry with an O--N-H distance of 2.9 A, suggesting a possibility of significant hydrogen bonding interaction. It should be noted that there is no experimental evidence for such interactions other than the modeling.) As a result of stabilization and activation of the nitrene intermediate of [Co(PI)] from the hydrogen bonding interaction, [Co(PI)] was expected to be a superior catalyst, in comparison with [Co(TPP)] and [Co(TDCIPP)], for aziridination with sulfonyl azides. (For an example of stabilization and activation of reactive intermediate by hydrogen bonding interactions, see: Lucas et al., J. Am. Chem. Soc. 2006, 128, 15476.)

[0061] [Co(PI)] was synthesized from its tetrabrominated precursor via a Pd- mediated quadruple amidation reaction with isobutylamide by following the previously established method. (Chen et al., J. Am. Chem. Soc. 2004, 126, 14718; Chen et al., J. Am. Chem. Soc. 2007, 129, 12074; Zhu et al., J. Am. Chem. Soc. 2008, 130, 5042.)

[Co(PI)] was readily prepared from reaction of P1 with CoCI ₂ in THF in the presence of 2,6-lutidine. Under the same conditions used for the aforementioned reactions by [Co(TPP)] and [Co(TDCIPP)], we were delighted to find that employment of [Co(PI)] resulted in a dramatic improvement of the catalytic aziridination (Reaction Scheme 4). The desired aziridines 2a, 2b, and 2c were obtained in 94%, 88%, and 98% isolated yields, respectively, supporting the hydrogenation bonding-guided catalyst design. ([Co(PI)] could effectively catalyze aziridination of styrene with PhI=NTs, forming the desired aziridines in 84% isolated yield.)

[0062] In addition to azides 1a, 1b, and 1c that contain -methyl, -methoxy, and -acetamide groups (Table 1 , entries 1-3), [Co(PI)] could effectively activate a wide range of arylsulfonyl azides for aziridination (Table 1). For example, the use of arylsulfonyl azides having para-cyano (1d), para-nitro (1e), and ortfto-nitro (1f) substituents afforded the corresponding aziridination products of styrene 2d-2f in excellent yields (Table 1 , entries 4-6). Naphthalene-1-sulfonyl azide 1g was found to be an equally active nitrene source (Table 1 , entry 7). Although the current [Co(PI )]-based catalytic system was ineffective for multiple substituted and aliphatic olefins, the [Co(PI )]-based catalytic aziridination system could be successfully applied to various combinations of arylsulfonyl azides and aromatic olefins (Table 2). For example, using azide 1e as a nitrene source, various styrene derivatives as well as 2-vinylnaphathene could be aziridinated in high to excellent yields (Table 2, entries 1-10). Similar results were obtained for azide 1c (Table 2, entries 11-14). While most of the reactions were carried out with 5 equiv. of olefin, the catalytic process could be operated with olefins as the limiting reagent as demonstrated with some selected examples, albeit in relatively lower yields (Table 2, entries 1 , 2, 5, 6, and 8).

[0063] In summary, guided by hydrogen bonding interaction in the proposed intermediate, we designed and synthesized the new porphyrin P1 whose Co complex [Co(PI)] was shown to be a highly effective catalyst for aziridination of aromatic olefins with arylsulfonyl azides under mild conditions. Efforts are underway to expand the substrate scope to include non-aromatic olefins and to develop its asymmetric variants.

TABLE 1 [Co(PI ]-Catalyzed Aziridination of Styrene with Azides ^a

TABLE 2 Aziridination of Aromatic Olefins with Azides by [Co(PI)] ^a

[0064] General Considerations. All cross-coupling and aziridination reactions were performed under nitrogen in oven-dried glassware following standard Schlenk techniques. 4 A molecular sieves were dried in a vacuum oven prior to use. Chlorobenzene and dichloromethane were dried over calcium hydride under nitrogen and freshly distilled before use. Toluene and tetrahydrofuran were distilled under nitrogen from sodium benzophenone ketyl prior to use. Acetoamidobenzenesulfonyl azide was purchased from Sigma-Aldrich and used without further purification. Arylsulfonyl chlorides were purchased from commercial sources. Thin layer chromatography was performed on Merck TLC plates (silica gel 60 F254). Flash column chromatography was performed with ICN silica gel (60 A, 230-400 mesh, 32-63 μm). ¹ H NMR and ¹³ C NMR were recorded on a Varian Inova400 (400 MHz) or a Varian InovaδOO (500 MHz) instrument with chemical shifts reported relative to residual solvent, lnfared spectra were measured with a Nicolet Avatar 320 spectrometer with a Smart Miracle accessory. HRMS data was obtained on an Agilent 1100 LC/MS/TOF mass spectrometer.

[0065] Porphyrin 1 (P1). An oven-dried Schlenk tube equipped with a stirring bar was degassed on vacuum line and purged with nitrogen. The tube was then charged with 5,15-Bis(2,6-dibromophenyl)-10,20-bis[3,5-di(tert-butyl)phen yl]porphyrin ( 0.2 mmol, 1 eq), isobutylamide (3.2 mmol, 16 eq), Pd(OAc) ₂ (0.08 mmol, 40%), Xantphos

(0.16 mmol, 80%), Cs ₂ CO ₃ (3.2 mmol, 16 eq). (Chen et al., J. Am. Chem. Soc. 2004, 126, 14718.) The tube was capped with a Teflon screw cap, evacuated and backfilled with nitrogen. After the Teflon screw cap was replaced with a rubber septum, solvent (4- 5 mL) was added via syringe. The tube was purged with nitrogen (1-2 min) and the septum was then replaced with the Teflon screw cap and sealed. The reaction mixture was heated in an oil bath at 100 ⁰ C with stirring for 72 hours. The resulting reaction mixture was concentrated and the solid residue was purified by flash chromatography (hexanes: ethyl acetate, 7: 3) to afford the compound as a purple solid (65 - 75%, in general). ¹ H NMR (400 MHz, CDCI ₃ ): δ 8.97 (d, J = 4.4 Hz, 4H), 8.85 (d, J = 4.8 Hz, 4H), 8.48 (d, J = 7.6 Hz, 4H), 8.00 (s, 4H), 7.90-7.85 (m, 4H) ₁ 6.46 (S ₁ 4H), 1.52 (s, 36H), 1.20 (m, 4H), 0.31 (d, J = 7.4 Hz, 24H), -2.53 (s, 2H). ¹³ C NMR (125 MHz, CDCI ₃ ): <y 174.7, 149.4, 139.7, 138.8, 133.5, 130.5, 130.1 , 123.1 , 121.8, 117.8, 108.0, 35.8, 35.0, 31.6, 18.5. UV-vis (CHCI ₃ ), λ _max , nm (log ε): 425(5.48), 519(4.19), 555(3.84), 595(3.70), 650(3.60). HRMS (ESI): Calcd. for C ₇₆ H _9I N ₈ O ₄ ([M+H] ⁺ ) m/z 1179.71578, Found 1179.71870.

[0066] Co[PI] Porphyrin Complex. Porphyrin 1 (0.054 mmol) and anhydrous CoCb (0.43 mmol) were placed in an oven-dried, re-sealable Schlenk tube. The tube was capped with a Teflon screw-cap, evacuated, and backfilled with nitrogen. The screw cap was replaced with a rubber septum, 2,6-lutidine (0.25 mmol) and dry THF (3- 4 mL) were added via syringe. The tube was purged with nitrogen for 1-2 minutes, and then the septum was replaced with the Teflon screw cap. The tube was sealed, and its

contents were heated in an oil bath at 80 ⁰ C with stirring overnight. The resulting mixture was cooled to room temperature, taken up in ethyl acetate, and transferred to a separatory funnel. The mixture was washed with water 3 times and concentrated. The solid residue was purified by flash chromatography (hexanes: ethyl acetate, 6: 4) to afford the compound as a purple solid (55.3 mg, 83% ). UV-vis (CHCI ₃ ), λ _max , nm (log ε): 415(5.23), 530(4.19). HRMS (ESI): Calcd. for C ₇₆ H ₈₈ N ₈ O ₄ Co ([M] ⁺ ) m/z 1235.62550, Found 1235.62638.

[0067] General Procedure for Synthesis of Azides. (Abramovitch et al., J. Org. Chem. 1977, 42, 2920; Waser et al., J. Am. Chem. Soc. 2006, 128, 1 1693; Brodsky et al., Org. Lett. 2004, 6, 2619.) A solution of the arylsulfonyl chloride in water: acetone (1 :1 , 6 ml/mmol) was stirred in a round bottom flask and cooled in an ice bath to 0 ⁰ C for 15-20 minutes. Sodium azide (1.5 eq) was added in portions to the sulfonyl chloride mixture and the reaction was monitored by TLC to completion (typically 2-5 hrs). After the reaction was complete, the flask underwent rotary evaporation until the acetone was removed. The crude product was extracted from the water using ethyl acetate or dichloromethane (3 x 5 ml/mmol). It was then washed with brine (10 ml/mmol), dried over sodium sulfate, and concentrated by rotary evaporation. The resulting oil was then purified by flash column chromatography. The fractions containing product were collected and concentrated by rotary evaporation to afford the compound.

[0068]4-Methylbenzenesulfonyl azide (1a, Table 1 , entry 1). ¹ H NMR (400 MHz,

CDCI ₃ ): £7.82 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 2.46 (s, 3H). IR (neat, cπV ¹ ): 2123, 1595, 1368, 1162, 1085, 813, 745, 657.

[0069]4-methoxybenzenesulfonyl azide (1b, Table 1 , entry 2) was obtained using the general procedure as white solid in 97% yield (5.0 g). ¹ H NMR (400 MHz, CDCI ₃ ): £7.89 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.8 Hz, 2H), 3.91 (s, 3H). IR (neat, cnT ¹ ): 2126, 1591 , 1550, 1518, 1496, 1461 , 1442, 1417, 1367, 1265, 1184, 1162, 1109, 1083, 1019, 831 , 804, 740, 666.

[0070]4-Cyanobenzenesulfonyl azide (1d, Table 1 , entry 4) was obtained using the general procedure as white solid in 76% yield (592 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.08 (d, J = BA Hz, 2H), 7.92 (d, J = 8.0 Hz, 2H). ¹³ C NMR (100 MHz, CDCI ₃ ): £ 142.3, 133.4, 128.0, 118.5, 116.6. IR (neat, crrf ¹ ): 2238, 2140, 1403, 1366, 1286, 1180, 1158, 1084, 1021 , 836, 800, 786, 751 , 631.

[0071]4-Nitrobenzenesulfonyl azide (1e, Table 1 , entry 5) was obtained using the general procedure as tan solid in 75% yield (7.76 g). ¹ H NMR (400 MHz, CDCI ₃ ): £8.46 (d, J = 8.8 Hz, 2H), 8.17 (d, J = 8.8 Hz, 2H). IR (neat, crrf ¹ ): 2140, 1605, 1528, 1404, 1374, 1349, 1310, 1175, 1156, 1109, 1084, 1013, 867, 854, 767, 740, 731 , 680.

[0072]2-Nitrobenzenesulfonyl azide (1f, Table 1 , entry 6) was obtained using the general procedure as white solid in 71% yield (7.3 g). ¹ H NMR (400 MHz, CDCI ₃ ): £ 8.19 (d, J = 7.6 Hz, 1 H), 7.92-7.80 (m, 3H). IR (neat, crrϊ ¹ ): 2162, 1593, 1552, 1533,

1437, 1366, 1314, 1194, 1171 , 1144, 1119, 1056, 966, 853, 782, 755, 736, 730, 694, 650, 605.

[0073] Naphthalene-1-sulfonyl azide (1g, Table 1 , entry 7) was obtained using the general procedure as white solid in 94 % yield (1.9 g). ¹ H NMR (400 MHz ₁ CDCI ₃ ): δ 8.57 (d, J = 8.8 Hz, 1H), 8.35 (d, J = 7.6 Hz, 1 H), 8.19 (d, J = 8.4 Hz, 1 H) ₁ 7.99 (d, J = 8.0 Hz, 1 H) ₁ 7.75 (t, J = 8.0 Hz ₁ 1 H), 7.66 (t, J = 7.6 Hz ₁ 1 H), 7.60 (t, J = 8.0 Hz, 1 H). ¹³ C NMR (100 MHz, CDCI ₃ ): 5136.3, 134.2, 133.4, 130.0, 129.1 , 128.0, 127.5, 134.4, 123.9. IR (neat, crrϊ ¹ ): 2131 , 1593, 1565, 1505, 1356, 1266, 1194, 1164, 1143, 1134, 1070, 1026, 975, 955, 921 , 863, 829, 796, 767, 737, 677, 626.

[0074] General Procedure for Aziridination. An oven dried Schlenk tube, that was previously evacuated and backfilled with nitrogen gas, was charged with azide (if solid, 0.2 mmol), catalyst (0.004 mmol), and 4A MS (100 mg). The Schlenk tube was then evacuated and back filled with nitrogen. The Teflon screw cap was replaced with a rubber septum and 0.2 ml portion of solvent was added followed by styrene (1.0 mmol), another portion of solvent, then azide (if liquid, 0.2 mmol), and the remaining solvent (total 1 ml_). The Schlenk tube was then purged with nitrogen for 1 minute and the rubber septum was replaced with a Teflon screw cap. The Schlenk tube was then placed in an oil bath for the desired time and temperature. Following completion of the reaction, the reaction mixture was purified by flash chromatography. The fractions containing product were collected and concentrated by rotary evaporation to afford the compound.

[0075]2-Phenyl-1-tosylaziridine (2a, Table 1 , entry 1) was obtained using the general procedure as colorless oil in 94% yield (51.4 mg). (Gao et al., Org. Lett. 2005, 7, 3191.) ¹ H NMR (400 MHz, CDCI ₃ ): £7.87 (d, J = 8.4 Hz, 2H) ₁ 7.33 (d, J = 8.4 Hz, 2H), 7.31-7.27 (m, 3H), 7.20 (m, 2H), 3.78 (dd, J = 7.2, 4.4 Hz, 1 H), 2.98 (d, J = 7.2 Hz, 1 H), 2.43 (s, 3H), 2.38 (d, J = 4.4 Hz, 1H). ¹³ C NMR (125 MHz, CDCI ₃ ): £ 144.5, 134.97, 134.91 , 129.6, 128.4, 128.2, 127.8, 126.4, 40.94, 35.84, 21.55. IR (neat, cm ^"1 ): 2923, 2854, 1595, 1495, 1458, 1385, 1319, 1307, 1290, 1232, 1188, 1155, 1134, 1117, 1093, 1082, 907, 815, 799, 780, 754, 711 , 696, 687, 662, 634. HRMS (ESI): Calcd. for Ci ₅ Hi ₆ NO ₂ S ([M+H] ⁺ ) m/z 274.08963, Found 274.08987.

[0076] 1-(4-Methoxyphenylsulfonyl)-2-phenylaziridine (2b, Table 1 , entry 2) was obtained using the general procedure as white solid in 88% yield (51.0 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £7.92 (d, J = 8.8 Hz, 2H), 7.28 (m, 3H), 7.21 (m, 2H), 6.99 (d, J = 8.8 Hz, 2H), 3.74 (dd, J = 7.2, 4.0 Hz, 1 H), 3.87 (s, 3H), 2.96 (d, J = 7.2 Hz, 1 H), 2.38 (d, J = 4.0 Hz, 1 H). ¹³ C NMR (125 MHz, CDCI ₃ ): £ 163.6, 135.0, 130.0, 129.3, 128.4, 128.2, 126.4, 114.2, 55.6, 40.9, 35.8. IR (neat, cnT ¹ ): 2958, 2924, 2854, 1592, 1576, 1498, 1458, 1442, 1322, 1301 , 1259, 1192, 1150, 1116, 1093, 1017, 908, 836, 805, 779, 755, 721 , 691 , 667, 629. HRMS (ESI): Calcd. for Ci ₅ Hi ₆ NO ₃ S ([M+H] ⁺ ) m/z 290.08454, Found 290.08488.

[0077] N-(4-(2-Phenylaziridin-1-ylsulfonyl)phenyl)acetamide (2c, Table 1, entry 3) was obtained using the general procedure as tan solid in 98% yield (62.2 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £7.90 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.61 (bs, 1 H), 7.27 (m, 3H), 7.20 (m, 2H), 3.76 (dd, J = 7.2, 4.4 Hz, 1 H), 2.97 (d, J = 7.2 Hz, 1 H), 2.39 (d, J = 4.4 Hz, 1 H), 2.19 (s, 3H). ¹³ C NMR (125 MHz, CDCI ₃ ): £ 168.8, 142.9, 134.7, 132.0, 129.1 , 128.5, 128.4, 126.4, 119.2, 41.1, 36.0, 24.6. IR (neat, crτT ¹ ): 3264, 2969, 2924, 1676, 1606, 1587, 1540, 1496, 1400, 1369, 1323, 1265, 1158, 1093, 908, 838, 823, 805, 779, 760, 728, 719, 697, 682, 668, 638, 623. HRMS (ESI): Calcd. for Ci ₆ H ₁₇ N ₂ O ₃ S ([M+H] ⁺ ) m/z 317.09544, Found 317.09508.

N

[0078]4-(2-Phenylaziridin-1-ylsulfonyl)benzonitrile (2d, Table 1 , entry 4) was obtained using the general procedure as a white solid in 89% yield (50.8 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.10 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.0 Hz, 2H), 7.30 (m, 3H), 7.21 (m, 2H), 3.88 (dd, J = 7.2, 4.8 Hz, 1 H), 3.08 (d, J = 7.2 Hz, 1 H), 2.48 (d, J = 4.8 Hz, 1 H). ¹³ C NMR (100 MHz, CDCI ₃ ): £206.9, 142.0, 133.5, 132.5 128.3, 128.1 , 126.1 , 117.0, 116.7, 41.4, 36.2. IR (neat, cnY ¹ ): 2233, 1458, 1403, 1333, 1291 , 1242, 1187, 1162, 119, 1094, 1020, 973, 909, 844, 797, 758, 749, 724, 699, 682, 644, 624. HRMS (ESI): Calcd. for C ₁₅ Hi ₃ N ₂ O ₂ S ([M+H] ⁺ ) m/z 285.06922, Found 285.07029.

[0079] 1-(4-Nitrophenylsulfonyl)-2-phenylaziridine (2e, Table 1 , entry 5) was obtained using the general procedure as a white solid in 97% yield (58.9 mg). (Mueller et al., Tetrahedron 1996, 52, 1543.) ¹ H NMR (400 MHz, CDCI ₃ ): £8.37 (d, J = 8.8 Hz, 2H), 8.19 (d, J = 8.8 Hz, 2H), 7.31 (m, 3H), 7.22 (m, 2H), 3.90 (dd, J = 7.2, 4.4 Hz, 1 H),

3.11 (d, J = 7.6 Hz, 1 H), 2.50 (d, J = AA Hz, I H)- ¹³ C NMR (^S MHZ ₁ CDCI ₃ ): δ 150.6, 143.9, 134.1, 129.1 , 128.7, 128.1, 126.4, 124.3, 41.8, 36.5. IR (neat, cm ^"1 ): 3110, 2923, 1607, 1527, 1461 , 1348, 1307, 1292, 1192, 1157, 1093, 977, 908, 866, 858, 811 , 774, 759, 745, 707, 691 , 680, 619. HRMS (ESI): Calcd. for Ci ₄ Hi ₃ N ₂ O ₄ S ([M+H] ⁺ ) m/z 305.05905, Found 305.05901.

[0080] 1-(2-Nitrophenylsulfonyl)-2-phenylaziridine (2f, Table 1 , entry 6) was obtained using the general procedure as tan oil in 96% yield (58.5 mg). (Kim et al., Angew. Chem., Int. Ed. 2004, 43, 3952.) ¹ H NMR (400 MHz, CDCI ₃ ): £8.23 (d, J = 6.4 Hz, 1 H), 7.74 (m, 3H), 7.32 (m, 5H), 3.76 (m, 1 H), 3.24 (d, J = 7.6 Hz, 1 H), 2.63 (d, J = 4.4 Hz, 1 H). ¹³ C NMR (125 MHz, CDCI ₃ ): £ 148.5, 134.6, 134.4, 132.1 , 131.9, 131.2, 128.59, 128.56, 126.5, 124.3, 42.8, 38.0. IR (neat, cm ^"1 ): 3094, 2921 , 1540, 1461 , 1365, 1331 , 1192, 1163, 1126, 1066, 1017, 979, 908, 851 , 774, 750, 745, 697, 654, 631. HRMS (ESI): Calcd. for Ci ₄ Hi ₃ N ₂ O ₄ S ([M+H] ⁺ ) m/z 305.05905, Found 305.05928.

[0081]1-(Naphthalen-1-ylsulfonyl)-2-phenylaziridine (2g, Table 1 , entry 7) was obtained using the general procedure as white solid in 97% yield (60.0 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £9.00 (d, J = 8.4 Hz, 1 H), 8.27 (d, J = 7.2 Hz, 1 H), 8.11 (d, J = 8.0 Hz, 1 H), 7.93 (d, J = 8.0 Hz, 1 H), 7.70 (t, J = 7.6 Hz, 1 H), 7.61 (t, J = 7.6 Hz, 1 H), 7.55 (t, J = 8.0 Hz, 1 H), 7.25 (m, 3H), 7.20 (m, 2H), 3.76 (m, 1 H), 3.09 (d, J = 7.2 Hz, 1 H), 2.38 (d, J = 4.4 Hz, 1 H). ¹³ C NMR (125 MHz, CDCI ₃ ): £135.17, 135.14, 134.1 , 133.3, 129.4, 129.0, 128.6, 128.4, 128.27, 128.22, 127.0, 126.4, 125.7, 123.9, 41.1 , 36.7. IR (neat, crrV ¹ ): 3060, 1594, 1507, 1459, 1384, 1319, 1191 , 1161 , 1132, 1110, 1083, 1027,

976, 906, 831 , 803, 768, 708, 694, 672, 627, 601. HRMS (ESI): Calcd. for Ci ₈ Hi ₆ NO ₂ S ([M+H] ⁺ ) m/z 310.08963, Found 310.08908.

[0082] 1-(4-Nitrophenylsulfonyl)-2-p-tolylaziridine (2h, Table 2, entry 2) was obtained using the general procedure as tan solid in 89% yield (56.5 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.36 (d, J = 8.8 Hz, 2H), 8.17 (d, J = 8.8 Hz, 2H), 7.10 (m, 4H), 3.86 (dd, J = 7.2, 4.8 Hz, 1 H), 3.10 (d, J = 7.2 Hz, 1 H), 2.50 (d, J = 4.8 Hz, 1H), 2.31 (s, 3H). ¹³ C NMR (125 MHz, CDCI ₃ ): £150.6, 144.0, 138.6, 131.0, 129.4, 129.1 , 126.3, 124.3, 41.9, 36.4, 21.1. IR (neat, crrf ¹ ): 3109, 2958, 1606, 1524, 1347, 1322, 1307, 1290, 1157, 1190, 1092, 977, 912, 866, 855, 817, 794, 752, 746, 729, 697, 679, 668, 611. HRMS (ESI): Calcd. TOr Ci ₅ Hi ₅ N ₂ O ₄ S ([M+H] ⁺ ) m/z 319.07470, Found 319.07413.

[0083]1-(4-Nitrophenylsulfonyl)-2-π?-tolylaziridine (2i, Table 2, entry 3) was obtained using the general procedure as tan solid in 89% yield (57.0 mg). (Li et al., J. Org. Chem. 2006, 71 , 5876.) ¹ H NMR (400 MHz, CDCI ₃ ): £8.37 (d, J = 8.8 Hz, 2H), 8.18 (d, J = 8.4 Hz, 2H), 7.20 (t, J = 8.0 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1 H), 7.01 (m, 2H), 3.86 (dd, J = 7.2, 4.8 Hz, 1 H), 3.09 (d, J = 7.2 Hz, 1 H), 2.50 (d, J = 4.8 Hz, 1H), 2.31 (s, 3H). ¹³ C NMR (125 MHz, CDCI ₃ ): £ 150.6, 143.9, 138.5, 134.0, 129.5, 129.1 , 128.6, 127.0, 124.3, 123.5, 41.9, 36.5, 21.3. IR (neat, crrT ¹ ): 3107, 2924, 1607, 1525, 1489, 1457, 1348, 1324, 1307, 1292, 1215, 1156, 1112, 1092, 979, 930, 900, 866, 854, 807, 783, 751 , 711 , 688, 669, 620. HRMS (ESI): Calcd. for Ci ₅ Hi ₅ N ₂ O ₄ S ([M+H] ⁺ ) m/z 319.07470, Found 319.07410.

[0084]1-(4-Nitrophenylsulfonyl)-2-o-tolylaziridine (2j, Table 2, entry 4) was obtained using the general procedure as tan solid in 88% yield (56.2 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.40 (d, J = 8.4 Hz, 2H), 8.22 (d, J = 8.4 Hz, 2H), 7.23-7.11 (m, 3H), 7.06 (d, J = 7.6 Hz, 1 H), 3.01 (m, 1 H), 3.10 (d, J = 7.2 Hz, 1 H), 2.43 (d, J = 4.8 Hz, 1 H), 2.41 (S ₁ 3H). ¹³ C NMR (125 MHz ₁ CDCI ₃ ): £150.6, 143.9, 136.7, 132.3, 130.1 , 129.2, 128.4, 126.2, 125.5, 124.3, 40.2, 35.8, 19.0. IR (neat, cnV ¹ ): 2980, 1607, 1524, 1349, 1328, 1306, 1243, 1203, 1158, 1092, 1012, 976, 907, 867, 829, 766, 744, 742, 698, 680, 668, 621. HRMS (ESI): Calcd. for Ci ₅ H ₁₅ N ₂ O ₄ S ([M+H] ⁺ ) m/z 319.07470, Found 319.07415.

[0085]2-(4-fert-Butylphenyl)-1-(4-nitrophenylsulfonyl)azirid ine (2k, Table 2, entry 5) was obtained using the general procedure as tan oil in 98% yield (71.0 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.37 (d, J = 8.4 Hz, 2H), 8.19 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 3.89 (m, 1H), 3.09 (d, J = 7.2 Hz, 1 H), 2.51 (d, J = 4.8 Hz, 1 H), 1.28 (s, 9H). ¹³ C NMR (125 MHz, CDCI ₃ ): £ 151.9, 150.6, 144.0, 131.0, 129.1, 126.1 , 125.6, 124.3, 41.9, 36.7, 34.6, 31.2. IR (neat, cm ^"1 ): 3060, 2964, 1594, 1533, 1507, 1459, 1320, 1191 , 1161 , 1133, 1110, 1086, 1027, 977, 907, 832, 804, 770, 744, 696, 673, 628, 604. HRMS (ESI): Calcd. for Ci ₈ H ₂₁ N ₂ O ₄ S ([M+H] ⁺ ) m/z 361.12165, Found 361.12077.

[0086]2-(4-Chlorophenyl)-1-(4-nitrophenylsulfonyl)aziridine (2I, Table 2, entry 6) was obtained using the general procedure as white solid in 94% yield (63.5 mg). (Leung et al., J. Am. Chem. Soc. 2005, 127, 16629.) ¹ H NMR (400 MHz, CDCI ₃ ): δ 8.37 (d, J = 8.8 Hz, 2H), 8.17 (d, J = 8.8 Hz, 2H), 7.28 (d, J = 8.8 Hz, 2H) ₁ 7.15 (d, J = 8.4 Hz, 2H), 3.87 (dd, J = 7.2, 4.8 Hz, 1 H) ₁ 3.10 (d, J = 7.2 Hz, 1 H), 2.54 (d, J = 4.8 Hz, 1 H). ¹³ C NMR (125 MHz, CDCI ₃ ): £ 150.6, 143.6, 134.6, 132.7, 129.1 , 128.9, 127.7, 124.3, 40.9, 36.7. IR (neat, cnT ¹ ): 3109, 2958, 2925, 1607, 1523, 1494, 1345, 1323, 1306, 1156, 1091 , 1016, 980, 911, 867, 834, 803, 753, 743, 724, 694, 680, 658, 630, 604. HRMS (ESI): Calcd. for Ci ₄ Hi ₂ N ₂ O ₄ SCI ([M+H] ⁺ ) m/z 339.02008, Found 339.02007.

[0087]2-(4-Bromophenyl)-1-(4-nitrophenylsulfonyl)aziridine (2m, Table 2, entry 7) was obtained using the general procedure as white solid in 96% yield (73.5 mg). (Ryan et al., Org. Biomol. Chem. 2004, 2, 3566.) ¹ H NMR (400 MHz, CDCI ₃ ): (58.38 (d, J = 8.8 Hz, 2H), 8.18 (d, J = 8.8 Hz, 2H), 7.20 (m, 2H), 7.00 (t, J = 8.4 Hz, 2H), 3.87 (m, 1 H), 3.09 (d, J = 7.2 Hz, 1 H), 2.45 (d, J = 4.4 Hz, 1 H). ¹³ C NMR (125 MHz, CDCI ₃ ): δ 150.6, 143.6, 133.2, 131.8, 129.1, 128.0, 124.3, 122.7, 41.1 , 36.6. IR (neat, crrf ¹ ): 2979, 2924, 1607, 1532, 1491 , 1336, 1348, 1319, 1161 , 1091 , 1009, 981 , 906, 854, 802, 769, 753, 739, 722, 688, 668, 625, 617. HRMS (ESI): Calcd. for Ci ₄ Hi ₂ N ₂ O ₄ SBr ([M+H] ⁺ ) m/z 382.96957, Found 382.96952.

[0088] 2-(4-Fluorophenyl)-1-(4-nitrophenylsulfonyl)aziridine ⁸ (2n, Table 2, Entry 8) was obtained using the general procedure as white solid in 95% yield (61.5 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.38 (d, J = 8.8 Hz ₁ 2H) ₁ 8.18 (d, J = 8.8 Hz, 2H), 7.19 (m, 2H) ₁ 7.00 (m, 2H), 3.88 (dd, J = 7.2, 4.4 Hz, 1 H), 3.09 (d, J = 7.2 Hz, 1 H), 2.47 (d, J = 4.4 Hz, 1 H). ¹³ C NMR (100 MHz ₁ CDCI ₃ ): £ 150.9, 143.9, 133.5, 132.1 , 129.4, 128.31 , 124.6, 123.0, 41.32, 36.92. IR (neat, cm ^"1 ): 3109, 1611 , 1523, 1512, 1455, 1348, 1323, 1308, 1292, 1231 , 1187, 1157, 1120, 1092, 981 , 91 1 , 868, 836, 817, 796, 754, 746, 734, 715, 695, 680, 611. HRMS (ESI): Calcd. for Ci ₄ Hi ₂ N ₂ O ₄ FS ([M+H] ⁺ ) m/z 323.04963, Found 323.04920.

[0089] 1 -(4-Nitrophenylsulfonyl)-2-(4-(trifluoromethyl)phenyl)azirid ine ⁷ (2o, Table 2, entry 9) was obtained using the general procedure as a white solid in 96% yield (71.8 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.39 (d, J = 8.4 Hz, 2H), 8.19 (d, J = 8.8 Hz ₁ 2H), 7.58 (d, J = 8.4 Hz ₁ 2H) ₁ 7.35 (d, J = 8.0 Hz, 2H) ₁ 3.94 (dd, J = 7.2, 4.8 Hz, 1 H), 3.14 (d, J = 7.2 Hz, 1 H), 2.48 (d, J = 4.4 Hz, 1 H). ¹³ C NMR (100 MHz, CDCI ₃ ): £ 150.8, 143.6, 138.3, 130.9 (CF ₃ ), 129.2, 126.8, 125.76, 125.73, 124.4, 40.83, 36.87. IR (neat, cm ^'1 ): 3112, 2927, 1621 , 1608, 1530, 1348, 1322, 1 162, 11 16, 1091 , 1066, 1017, 982, 909, 849, 756, 713, 696, 630. HRMS (ESI): Calcd. for Ci ₅ Hi ₂ N ₂ O ₄ F ₃ S ([M+H] ⁺ ) m/z 373.04644, Found 373.04658.

[0090]2-(Naphthalen-2-yl)-1-(4-nitrophenylsulfonyl)aziridine (2p, Table 2, entry 10) was obtained using the general procedure as tan solid in 75% yield (53.5 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.38 (d, J = 8.4 Hz, 2H), 8.21 (d, J = 8.8 Hz, 2H), 7.81 (m, 3H), 7.74 (s, 1 H), 7.50 (m, 2H), 7.27 (m, 1H), 4.07 (m, 1H), 3.20 (d, J = 7.2 Hz ₁ 1 H), 2.63 (d, J = 4.4 Hz, 1H). ¹³ C NMR (125 MHz, CDCI ₃ ): £ 150.6, 143.9, 133.2, 132.9, 131.4, 129.1 , 128.7, 127.75, 127.73, 126.6, 126.5, 126.2, 124.3, 123.2, 42.2, 36.6. IR (neat, crτf ¹ ): 3107, 2922, 1604, 1529, 1401 , 1346, 1326, 1305, 1156, 1092, 949, 917, 862, 852, 800, 767, 742, 713, 679, 669, 640, 623, 608. HRMS (ESI): Calcd. for Ci ₈ H ₁₅ N ₂ O ₄ S ([M+H] ⁺ ) m/z 355.07470, Found 355.07456.

[0091] N-(4-(2-p-Tolylaziridin-1-ylsulfonyl)phenyl)acetamide (2q, Table 2, entry 12) was obtained using the general procedure as tan oil in 83% yield (55.1 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £7.98 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.08 (s, 4H) ₁ 3.71 (dd, J = 6.8, 4.4 Hz, 1 H), 2.93 (d, J = 6.8 Hz, 1 H), 2.39 (d, J = 4.4 Hz, 1 H), 2.29 (S ₁ 3H), 2.16 (s, 3H). ¹³ C NMR (100 MHz, CDCI ₃ ): £ 168.9, 148.9, 138.3, 132.0, 131.6, 129.2, 129.1 , 126.3, 119.2, 41.2, 35.8, 24.6, 21.2. IR (neat, crrT ¹ ): 3346, 3111 , 1701 , 1590, 1529, 1402, 1370, 1320, 1261 , 1155, 1093, 909, 820, 731 , 683, 635, 619. HRMS (APCI): Calcd. for Ci ₇ Hi ₉ N ₂ O ₃ S ([M+H] ⁺ ) m/z 331.11109, Found 331.11052.

[0092] N-(4-(2-(4-te/t-Butylphenyl)aziridin-1 -ylsulfonyl)phenyl)acetamide (2r, Table 2, entry 13) was obtained using the general procedure as tan oil in 84% yield (62.3 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £8.00 (s, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 8.8 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 3.74 (dd, J = 7.2, 4.8 Hz, 1H), 2.94 (d, J = 7.2 Hz, 1 H), 2.39 (d, J = 4.8 Hz, 1 H), 2.17 (s, 3H), 1.27 (s, 9H). ¹³ C NMR (100 MHz, CDCI ₃ ): £ 169.0, 151.5, 143.0, 132.0, 131.6, 129.1 , 126.2, 125.5, 119.2, 41.1 , 35.9, 34.5, 31.2, 24.5. IR (neat, crrf ¹ ): 3334, 2965, 1703, 1591 , 1529, 1402, 1365, 1321 , 1263, 1156, 1093, 910, 839, 749, 731 , 689, 639, 617. HRMS (APCI): Calcd. for C ₂₀ H ₂₅ N ₂ O ₃ S ([M+H] ⁺ ) m/z 373.15804, Found 373.15904.

[0093] N-(4-(2-(4-Chlorophenyl)aziridin-1 -ylsulfonyl)phenyl)acetamide (2s, Table 2, entry 14) was obtained using the general procedure as tan oil in 93% yield (65.3 mg). ¹ H NMR (400 MHz, CDCI ₃ ): £7.98 (s, 1 H), 7.84 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 3.68 (dd, J = 7.2, 4.4 Hz, 1 H), 2.93 (d, J = 7.2 Hz, 1 H), 2.33 (d, J = 4.4 Hz, 1H), 2.16 (s, 3H). ¹³ C NMR (100 MHz, CDCI ₃ ): £ 168.9, 143.1 , 134.2, 133.3, 131.8, 129.1 , 128.7, 127.8, 119.2, 40.3, 36.1 , 24.7. IR (neat, cm ^'1 ): 3333, 3112, 1701 , 1590, 1529, 1494, 1402, 1370, 1322, 1262, 1156, 1092, 1014, 981 , 908, 827, 776, 735, 689, 637, 623, 613. HRMS (APCI): Calcd. for Ci ₆ H ₁₆ N ₂ O ₃ SCI ([M+H] ⁺ ) m/z 351.05647, Found 351.05748.

TABLE 3 Asymmetric Olefin Aziridination with Azides by Chiral Cobalt Porphyins

Co(Porl )

Co(Por2)

Co(Por3)